Literature DB >> 25208551

Age-specific incidence, outcome, cost, and projected future burden of atrial fibrillation-related embolic vascular events: a population-based study.

Gabriel S C Yiin1, Dominic P J Howard1, Nicola L M Paul1, Linxin Li1, Ramon Luengo-Fernandez1, Linda M Bull1, Sarah J V Welch1, Sergei A Gutnikov1, Ziyah Mehta1, Peter M Rothwell2.   

Abstract

BACKGROUND: Prevalence of atrial fibrillation (AF) is >10% at age ≥80 years, but the impact of population aging on rates of AF-related ischemic events is uncertain. METHODS AND
RESULTS: We studied age-specific incidence, outcome, and cost of all AF-related incident strokes and systemic emboli from 2002 to 2012 in the Oxford Vascular Study (OXVASC). We determined time trends in incidence of AF-related stroke in comparison with a sister study in 1981 to 1986, extrapolated numbers to the UK population and projected future numbers. Of 3096 acute cerebral or peripheral vascular events in the 92 728 study population, 383 incident ischemic strokes and 71 systemic emboli were related to AF, of which 272 (59.9%) occurred at ≥80 years. Of 597 fatal or disabling incident ischemic strokes, 262 (43.9%) were AF-related. Numbers of AF-related ischemic strokes at age ≥80 years increased nearly 3-fold from 1981-1986 to 2002-2012 (extrapolated to the United Kingdom: 6621 to 18 176 per year), due partly to increased age-specific incidence (relative rate 1.52, 95% confidence interval 1.31-1.77, P=0.001), with potentially preventable AF-related events at age ≥80 years costing the United Kingdom £374 million per year. At current incidence rates, numbers of AF-related embolic events at age ≥80 years will treble again by 2050 (72 974/year), with 83.5% of all events occurring in this age group.
CONCLUSIONS: Numbers of AF-related incident ischemic strokes at age ≥80 years have trebled over the last 25 years, despite the introduction of anticoagulants, and are projected to treble again by 2050, along with the numbers of systemic emboli. Improved prevention in older people with AF should be a major public health priority.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  atrial fibrillation; atrial flutter; embolism; population; stroke

Mesh:

Substances:

Year:  2014        PMID: 25208551      PMCID: PMC5384634          DOI: 10.1161/CIRCULATIONAHA.114.010942

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  41 in total

1.  Experience from a multicentre stroke register: a preliminary report.

Authors:  S Hatano
Journal:  Bull World Health Organ       Date:  1976       Impact factor: 9.408

2.  Bleeding risk with dabigatran in the frail elderly.

Authors:  Paul Harper; Laura Young; Eileen Merriman
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

3.  Atrial fibrillation and stroke in the general medicare population: a 10-year perspective (1992 to 2002).

Authors:  Kamakshi Lakshminarayan; Craig A Solid; Allan J Collins; David C Anderson; Charles A Herzog
Journal:  Stroke       Date:  2006-06-29       Impact factor: 7.914

4.  Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.

Authors:  John W Eikelboom; Lars Wallentin; Stuart J Connolly; Mike Ezekowitz; Jeff S Healey; Jonas Oldgren; Sean Yang; Marco Alings; Scott Kaatz; Stefan H Hohnloser; Hans-Christoph Diener; Maria Grazia Franzosi; Kurt Huber; Paul Reilly; Jeanne Varrone; Salim Yusuf
Journal:  Circulation       Date:  2011-05-16       Impact factor: 29.690

5.  Incident thromboembolism in the aorta and the renal, mesenteric, pelvic, and extremity arteries after discharge from the hospital with a diagnosis of atrial fibrillation.

Authors:  L Frost; G Engholm; S Johnsen; H Møller; E W Henneberg; S Husted
Journal:  Arch Intern Med       Date:  2001-01-22

Review 6.  Epidemic obesity and type 2 diabetes in Asia.

Authors:  Kun-Ho Yoon; Jin-Hee Lee; Ji-Won Kim; Jae Hyoung Cho; Yoon-Hee Choi; Seung-Hyun Ko; Paul Zimmet; Ho-Young Son
Journal:  Lancet       Date:  2006-11-11       Impact factor: 79.321

7.  Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators.

Authors:  Carl van Walraven; Robert G Hart; Stuart Connolly; Peter C Austin; Jonathan Mant; F D Richard Hobbs; Peter J Koudstaal; Palle Petersen; Francisco Perez-Gomez; J Andre Knottnerus; Beppie Boode; Michael D Ezekowitz; Daniel E Singer
Journal:  Stroke       Date:  2009-01-29       Impact factor: 7.914

8.  Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates.

Authors:  W B Kannel; P A Wolf; E J Benjamin; D Levy
Journal:  Am J Cardiol       Date:  1998-10-16       Impact factor: 2.778

9.  Stroke associated with atrial fibrillation--incidence and early outcomes in the north Dublin population stroke study.

Authors:  Niamh Hannon; Orla Sheehan; Lisa Kelly; Michael Marnane; Aine Merwick; Alan Moore; Lorraine Kyne; Joseph Duggan; Joan Moroney; Patricia M E McCormack; Leslie Daly; Nicola Fitz-Simon; Dawn Harris; Gillian Horgan; Emma B Williams; Karen L Furie; Peter J Kelly
Journal:  Cerebrovasc Dis       Date:  2009-11-05       Impact factor: 2.762

10.  A population-based study of hospital care costs during 5 years after transient ischemic attack and stroke.

Authors:  Ramon Luengo-Fernandez; Alastair M Gray; Peter M Rothwell
Journal:  Stroke       Date:  2012-11-15       Impact factor: 7.914

View more
  43 in total

Review 1.  Cardioembolic Stroke.

Authors:  Hooman Kamel; Jeff S Healey
Journal:  Circ Res       Date:  2017-02-03       Impact factor: 17.367

Review 2.  Stroke Risk Factors, Genetics, and Prevention.

Authors:  Amelia K Boehme; Charles Esenwa; Mitchell S V Elkind
Journal:  Circ Res       Date:  2017-02-03       Impact factor: 17.367

3.  Atrial fibrillation and stroke prevention: where we are and where we should be.

Authors:  Nicholas R Jones; Fd Richard Hobbs; Clare J Taylor
Journal:  Br J Gen Pract       Date:  2018-06       Impact factor: 5.386

4.  Endovascular treatment of acute ischemic stroke in nonagenarians compared with younger patients in a multicenter cohort.

Authors:  Muhib A Khan; Grayson L Baird; David Miller; Anand Patel; Shawn Tsekhan; Shadi Yaghi; Ajit Puri; Mahesh Jayaraman; Nils Henninger; Brian Silver
Journal:  J Neurointerv Surg       Date:  2016-07-11       Impact factor: 5.836

5.  Anticoagulation in patients at high risk of stroke without documented atrial fibrillation. Time for a paradigm shift?

Authors:  Antoni Bayés de Luna; Adrian Baranchuk; Manuel Martínez-Sellés; Pyotr G Platonov
Journal:  Ann Noninvasive Electrocardiol       Date:  2016-12-16       Impact factor: 1.468

6.  Atrial Cardiopathy and the Risk of Ischemic Stroke in the CHS (Cardiovascular Health Study).

Authors:  Hooman Kamel; Traci M Bartz; Mitchell S V Elkind; Peter M Okin; Evan L Thacker; Kristen K Patton; Phyllis K Stein; Christopher R deFilippi; Rebecca F Gottesman; Susan R Heckbert; Richard A Kronmal; Elsayed Z Soliman; W T Longstreth
Journal:  Stroke       Date:  2018-03-13       Impact factor: 7.914

7.  Management of Complications in Anticoagulated Patients with Atrial Fibrillation.

Authors:  George D Katritsis; Demosthenes G Katritsis
Journal:  Arrhythm Electrophysiol Rev       Date:  2017-12

8.  Electrical cardioversion for supraventricular arrhythmias in octagenarians.

Authors:  Felipe L Malafaia; Patrícia O Guimarães; Márcio C Sampaio; Pedro G M de Barros E Silva; Renato D Lopes; Juliano V Custódio; Miguel da S Diniz; José C T Garcia; Valter Furlan
Journal:  J Geriatr Cardiol       Date:  2019-12       Impact factor: 3.327

Review 9.  Atrial cardiopathy: a broadened concept of left atrial thromboembolism beyond atrial fibrillation.

Authors:  Hooman Kamel; Peter M Okin; W T Longstreth; Mitchell S V Elkind; Elsayed Z Soliman
Journal:  Future Cardiol       Date:  2015-05

10.  Real World Outcomes of Left Atrial Appendage Occlusion.

Authors:  Apostolos Tzikas; Darren Mylotte; Martin Bergmann
Journal:  Interv Cardiol       Date:  2015-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.